Epizyme (EPZM) 10-Q2022 Q1 Quarterly report

Filed: 10 May 22, 7:26am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	Coll freshman Avg

New words: add, appeal, ARIA, ASCO, ASH, assumption, Bayesian, bid, breadth, calendar, capacity, ceased, Chicago, clarify, Concurrent, consecutive, copy, CRO, deep, deficiency, delisted, delisting, Department, deployment, embraced, entity, exhibit, fail, feedback, foregoing, freestanding, indexed, interval, landscape, MediPharma, notifying, objection, overlapping, oversight, packaging, panel, pending, poster, publicly, purport, recommended, regain, remove, removed, reprioritization, screen, screening, simplify, split, startup, Subtopic, suffering, sustain, Treasury, unpredictable, upcoming, waiting, widespread

Removed: abiraterone, absent, academic, acetyltransferase, acquired, acquiring, AG, ALIQOPA, arginine, assign, assume, authorization, Bio, bispecific, Boehringer, bringing, broadly, build, Celgene, collaborative, commence, Committee, compete, complementary, composition, compound, concentrated, Constellation, constitute, convenient, copanlisib, COPIKTRA, Daiichi, demonstrating, developed, discovering, dosing, dual, duvelisib, encourage, EPIC, EPIsode, establish, establishing, Europe, evaluable, expensed, expensive, expired, exploit, fewer, final, force, Gilead, GmbH, HAT, helicase, Hengrui, highly, idelalisib, Immunotherapy, impacted, indirectly, infrastructure, Ingelheim, International, Jiangsu, Johnson, Joint, jointly, JSC, Kite, lack, lead, lend, line, malignant, Maximize, men, Merck, monoclonal, MRT, negatively, Otsuka, ovarian, par, partial, participant, Pfizer, Pharma, positively, predictive, prednisone, priced, profile, progressed, protein, PSA, quickly, radiographic, rapidly, reacquisition, reciprocal, recruiting, resistant, rhabdoid, Rituxan, safer, Sankyo, Secura, shareholder, showed, side, smaller, soft, SoLO, specifically, Spectrum, Squibb, Steering, targeting, therapy, tissue, transformative, treat, UKONIQ, umbralisib, understand, undisclosed, unexercised, valemetostat, vested, vision, YESCARTA, ZYDELIG

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EPZM transcripts

EPZM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Epizyme, Inc. (the “Company”) for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Grant Bogle, President and Chief Executive Officer of the Company (Principal Executive Officer and Principal Financial Officer), hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 10, 2022

/s/ Grant Bogle

Grant Bogle

President and Chief Executive Officer

(Principal Executive Officer and Principal Financial Officer)